Antiretroviral therapy
Antiretroviral therapy has been studied in 228 papers since 2010: 2 trials and 137 observational studies in people, 2 in animals, 84 reviews; 69 in the past year. The newest paper, Nov 11, 2026: “Prevalence and Factors Associated with Erectile Dysfunction Among Men Living with HIV: A Systematic Review, Meta-Analysis, and Meta-Regression”.
228 papers study it148 findingsUpdated
Research on it is growing 10% faster than aging research as a whole: 54 papers in the latest year counted
10 new papers in 30 daysSee all 226 papers on antiretroviral therapy
At a glance
Independent labs found the same change in people. 54 independent labs in 27 countries.
“Markers of CD4(+) T-cell senescence (ie, the percentage of CD28(-)CD57(+) cells among CD4(+) T cells ) and CD4(+)/CD8(+) T-cell exhaustion (ie, the percentage of PD-1(+) cells among CD4(+)/CD8(+) T cells) decreased after ART.”
7 of its findings point the other way.
- 54 independent labs in 27 countries
- 7 findings against
- Funders: National Institutes of Health and others
- 8 of 92 findings with company ties
- Human trial2
- Humans136
- Animals2
- In silico1
Studies in people
2 studies gave antiretroviral therapy to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases epigenetic age | Randomized trial2 years | 168 peopleIn ART-naive adults with HIV, before versus after ART initiation | The lancet. HIV, Apr 1, 2021 |
down: Decreases PD-1+ T cells no change: Has no effect on CD8+ T-cell senescence markers | Randomized trial96-week | 328 peoplePatient cohorts | The Journal of infectious diseases, Jun 28, 2016 |
What did studies of antiretroviral therapy find?
53Studies of antiretroviral therapy measured 53 outcomes; the most studied are lifespan (24 studies), cellular senescence (5) and life expectancy (4).
Lifespan
upin humans24
24 studies
Lifespan
upin humans24
Antiretroviral therapy extends lifespan in humans (people living with HIV).
“Although antiretroviral therapy (ART) has extended the lifespan of people living with HIV (PWH), many experience complex age-related comorbidities and functional decline.”
Reviewpeople living with HIV
The Journal of the Association of Nurses in AIDS Care : JANAC
Antiretroviral therapy extends lifespan in humans.
“This ART paradox reflects the unintended consequence of extending WLHIV lifespan into cancer-vulnerable age cohorts”
Reviewfemales
International journal of women's health
Antiretroviral therapy extends lifespan in people living with HIV.
“Advances in antiretroviral therapy (ART) have extended the life expectancy of people living with HIV (PWH) in Peru”
Reviewin people living with HIV
A Review of Chronic Comorbidities in People Living With HIV in Peru
Journal of the International Association of Providers of AIDS Care
Antiretroviral therapy extends lifespan in people living with HIV.
“Antiretroviral therapy has extended the lifespan of HIV/ADIS.”
Reviewin people living with HIV
Journal of infection and public health
Antiretroviral therapy extends lifespan in humans.
“With the extensive implementation of antiretroviral therapy (ART), the life expectancy of people living with HIV (PLWH) has markedly extended.”
Review
HIV infection, antiretroviral therapy and vascular dysfunction: Effects, mechanisms and treatments
Pharmacological research
Antiretroviral therapy extends lifespan in persons with HIV in the United States.
“average lifespans of persons with HIV (PWH) in the United States have increased significantly in recent decades”
Reviewin persons with HIV in the United States
Aging and mortality of persons with HIV: a novel Kalman Filtering and DMD framework
arXiv (Cornell University)Preprint
Antiretroviral therapy extends lifespan in people living with HIV.
“The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV.”
Reviewin people living with HIV
Prevention and control of HPV-related cancers in people living with HIV
The lancet. HIV
Antiretroviral therapy extends lifespan in people living with HIV.
“The increasing lifespan of people living with HIV (PLWH) due to advancements in antiretroviral therapy (ART)”
Reviewin people living with HIV
A Comprehensive Review of the Manifestation of Cardiovascular Diseases in HIV Patients
Cureus
Antiretroviral therapy extends lifespan in humans (HIV).
“antiretroviral therapy (ART) has resulted in significant improvement in life expectancy for people with HIV.”
ReviewHIV
Challenges of HIV Management in an Aging Population
Current HIV/AIDS reports
Antiretroviral therapy extends lifespan in humans (HIV care) (dramatically extended).
“Integrating antiretroviral therapy into HIV care dramatically extended the lifespan for people living with HIV.”
ReviewHIV care
The journals of gerontology. Series A, Biological sciences and medical sciences
All 24Fewer
Cellular senescence
upin humans2no changein humans2downin humans1
5 studies
Cellular senescence
upin humans2no changein humans2downin humans1
Antiretroviral therapy showed no clear effect on cellular senescence in acute HIV infection.
“which were not normalized by early ART.”
Human trialin acute HIV infectionPBMC
FoxP3⁺ CD8 T-cells in acute HIV infection and following early antiretroviral therapy initiation
Frontiers in immunology
Antiretroviral therapy is linked with cellular senescence in humans.
“We showed that continuous ART induces a progressive senescence-like pro-inflammatory state in AM characterized by increased constitutive epigenetic and transcriptomic priming of genes involved in cell-cycle arrest and senescence.”
Humansalveolar macrophages
Frontiers in immunology
Antiretroviral therapy was not clearly linked with cellular senescence in humans (chronic and advanced HIV infection, one year on ART).
“which generally persisted after ART, but not in PWH treated in primary HIV infection”
Humanschronic and advanced HIV infection, one year on ARTT cell, monocyteone yearmalesn = 39
The Journal of infectious diseases
Antiretroviral therapy is linked with lower cellular senescence in humans (compared to late-suppressed and not-suppressed PHIVAYA).
“ES-PHIVAYA exhibited significantly lower HIV-DNA reservoir, decreased percentages of senescent and exhausted CD4 and CD8 T cells”
Humanscompared to late-suppressed and not-suppressed PHIVAYAbloodn = 6
PLoS pathogens
Antiretroviral therapy induces cellular senescence in humans.
“HIV patients experience several stressors such as the virus itself, antiretroviral drugs and to a lesser extent, substance abuse that can induce cellular senescence.”
Review
HIV-associated cellular senescence: A contributor to accelerated aging
Ageing research reviews
Life expectancy
upin humans4
4 studies
Life expectancy
upin humans4
Antiretroviral therapy improves life expectancy in humans.
“Antiretroviral therapy has extended the life expectancy of people with HIV (PWH)”
Review
HIV infection and immunosenescence: challenges and intervention strategies
BMC medicine
Antiretroviral therapy improves life expectancy in humans (people living with HIV).
“The advent of antiretroviral therapy has markedly improved the life expectancy of individuals with HIV”
Reviewpeople living with HIV
Atherosclerosis and HIV: Exploring Cardiovascular Risks and Management
Cardiology in review
Antiretroviral therapy improves life expectancy in people with HIV.
“The drastic improvement in life expectancy of people with HIV has led to an expansion of the aging population of people with HIV globally.”
Reviewin people with HIV
Neurocognition and the Aging Brain in People With HIV: Implications for Screening
Topics in antiviral medicine
Antiretroviral therapy increases life expectancy in humans (people living with HIV).
“With the introduction of effective antiretroviral therapy, the life expectancy of people living with HIV has improved.”
Reviewpeople living with HIV
Ageing in patients with chronic HIV infection: impact of hypercoagulation
AIDS research and therapy
Epigenetic age
downin humans3
3 studies
Epigenetic age
downin humans3
Antiretroviral therapy decreases epigenetic age in ART-naive adults with HIV, before versus after ART initiation.
“After 2 years of ART, epigenetic age acceleration was reduced”
Human trialin ART-naive adults with HIV, before versus after ART initiationwhole blood2 yearsn = 168
The lancet. HIV
Antiretroviral therapy is linked with lower epigenetic age in humans (people living with HIV).
“ART therapy mitigated the advancement of DNA methylation age.”
Humanspeople living with HIV
Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with HIV
Cancer medicine
Antiretroviral therapy decreases epigenetic age in people with HIV.
“Epigenetic age acceleration (EAA) in PWH has now clearly been shown to be potentially reversible during successful antiretroviral therapy (ART).”
Reviewin people with HIV
Perspective: clinical relevance of epigenetic aging and HIV
Epigenomics
Mortality
downin humans3
3 studies
Mortality
downin humans3
Antiretroviral therapy decreases mortality in humans (living with HIV).
“Antiretroviral therapy (ART) has significantly improved mortality rates for individuals living with HIV”
Reviewliving with HIV
Burden of Kidney Disease in an Aging Population Living with HIV in the United States
AIDS patient care and STDs
Antiretroviral therapy decreases mortality in HIV-infected people.
“The mortality rate associated with HIV infection plummeted after the introduction of effective antiretroviral therapy pioneered two decades ago.”
Reviewin HIV-infected people
Understanding mechanisms to promote successful aging in persons living with HIV
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Antiretroviral therapy decreases mortality in humans (HIV infection).
“Although introduction of antiretroviral therapy (ART) has led to significant reduction in morbidity and mortality of HIV-infected patients, viral replication persists.”
ReviewHIV infection
HIV Infection and Compromised Mucosal Immunity: Oral Manifestations and Systemic Inflammation
Frontiers in immunology
PhenoAge
no changein humans2
2 studies
PhenoAge
no changein humans2
Antiretroviral therapy was not clearly linked with PhenoAge in humans (virally suppressed on ART) (-0.38 vs -0.47 years).
“the median PAA values at T0 and T5 were -0.38 and -0.47 years, indicating non-significant change over five years”
Humansvirally suppressed on ART5 yearsn = 728
The journals of gerontology. Series A, Biological sciences and medical sciences
Antiretroviral therapy was not clearly linked with PhenoAge in humans (long-term aviremic HIV-infected adults on stable ART).
“After 4 years of follow-up, PhenoAge-EAA and GrimAge-EAA showed no differences”
Humanslong-term aviremic HIV-infected adults on stable ART4 yearsn = 63
The Journal of infectious diseases
Inflammation
downin humans1upin humans1
2 studies
Inflammation
downin humans1upin humans1
Antiretroviral therapy is linked with inflammation in humans.
“We showed that continuous ART induces a progressive senescence-like pro-inflammatory state in AM”
Humansalveolar macrophages
Frontiers in immunology
Antiretroviral therapy decreases inflammation in HIV-infected microglia.
“ART mitigates these effects but does not fully restore to levels observed in HIV-uninfected conditions.”
Reviewin HIV-infected microgliabrain
Implications of HIV persistence and pathogenesis in microglia
Current opinion in HIV and AIDS
Biological age
downin humans2
2 studies
Biological age
downin humans2
Antiretroviral therapy is linked with lower biological age in people with HIV.
“specific antiretroviral drugs reduce age acceleration”
Humansin people with HIV
Nature communications
Antiretroviral therapy decreases biological age in people living with HIV.
“The ART initiation reverses the biological ageing process but only partially”
Reviewin people living with HIV
Ageing with HIV: Challenges and biomarkers
EBioMedicine
Horvath clock
downin humans2
2 studies
Horvath clock
downin humans2
Antiretroviral therapy is linked with lower Horvath clock in humans (people with HIV on suppressive ART) (-0.35 years/year (95% CI -0.44 to -0.27)).
“Per year of suppressive ART (median observation 9·8 years, IQR 7·2-11), mean EAA was -0·35 years (95% CI -0·44 to -0·27) for Horvath's clock”
Humanspeople with HIV on suppressive ARTperipheral blood mononuclear cellsmedian observation 9.8 years (IQR 7.2-11)n = 80
The lancet. Healthy longevity
Antiretroviral therapy is linked with lower Horvath clock in humans (long-term aviremic HIV-infected adults on stable ART) (median difference, -0.53 years, P = .015).
“whereas Horvath-EAA slightly decreased (median difference, -0.53 years; P = .015).”
Humanslong-term aviremic HIV-infected adults on stable ART4 yearsn = 63
The Journal of infectious diseases
p16INK4a
no changein humans1downin humans1
1 study
p16INK4a
no changein humans1downin humans1
Antiretroviral therapy was not clearly linked with p16INK4a in humans (chronically HIV-infected patients).
“ART restored p16 protein expression to levels comparable with HIV-negative subjects in the CD4 compartment, but not in CD8 T cells”
Humanschronically HIV-infected patientsCD8 T cells
p16INK4a Expression and Immunologic Aging in Chronic HIV Infection
PloS one
Antiretroviral therapy is linked with lower p16INK4a in humans (chronically HIV-infected patients).
“ART restored p16 protein expression to levels comparable with HIV-negative subjects in the CD4 compartment”
Humanschronically HIV-infected patientsCD4 T cells
p16INK4a Expression and Immunologic Aging in Chronic HIV Infection
PloS one
KLRG1
upin humans1
1 study
KLRG1
upin humans1
Antiretroviral therapy increases KLRG1 in PWH during the first 4 y of ART.
“accompanied an overall increase in NK surface expression of CD57 and KLRG1, suggestive of progression toward immune senescence.”
Human trialin PWH during the first 4 y of ART4 yn = 60
Journal of immunology (Baltimore, Md. : 1950)
CD57
upin humans1
1 study
CD57
upin humans1
Antiretroviral therapy increases CD57 in PWH during the first 4 y of ART.
“Throughout this regimen, a skewed repertoire of cytokine unresponsive FcRγ- memory-like NK cells persisted and accompanied an overall increase in NK surface expression of CD57 and KLRG1”
Human trialin PWH during the first 4 y of ART4 yn = 60
Journal of immunology (Baltimore, Md. : 1950)
FoxP3+ CD8 T-cells
downin humans1
1 study
FoxP3+ CD8 T-cells
downin humans1
Antiretroviral therapy decreases FoxP3+ CD8 T-cells in acute HIV infection.
“early ART normalized only the frequencies of total FoxP3+ CD8 T-cells.”
Human trialin acute HIV infectionPBMCmedian 5.5 months post-infection
FoxP3⁺ CD8 T-cells in acute HIV infection and following early antiretroviral therapy initiation
Frontiers in immunology
Blood telomere length
upin humans1
1 study
Blood telomere length
upin humans1
Antiretroviral therapy increases blood telomere length in humans after 96 weeks of first-line antiretroviral therapy in HIV-1-positive individuals (+0.04 T/S ratio).
“we found after 96 weeks a statistically significant increase in blood telomere length (TL) of 0.04 (T/S Ratio) (p = 0.03)”
Human trialafter 96 weeks of first-line antiretroviral therapy in HIV-1-positive individualsblood96 weeksn = 31
PloS one
CD127+ CD8+ T cells
upin humans1
1 study
CD127+ CD8+ T cells
upin humans1
Antiretroviral therapy increases CD127+ CD8+ T cells in humans after initiation of ART.
“The frequency of CD127+ CD8+ cells increased in Tcm and TemRO.”
Human trialafter initiation of ART
Clinical and experimental immunology
All 53Fewer
What is antiretroviral therapy linked with?
46Studies link antiretroviral therapy with 46 measures, most often frailty (4 studies), metabolic syndrome (2) and multimorbidity (2).
Frailty
upin humans3downin humans1
4 studies
Frailty
upin humans3downin humans1
Antiretroviral therapy is linked with a higher risk of frailty in PLWH.
“prolonged ARV exposure and polypharmacy significantly increase frailty risk.”
Humansin PLWH
Influence of antiretroviral therapy on frailty among people living with HIV
Scientific reports
Antiretroviral therapy is linked with a lower risk of frailty in humans (independent of age and years lived with HIV) (aOR 0.39, 95% CI 0.19-0.78).
“each 5 years of ART use was associated with 60% lower odds of frailty/pre-frailty (aOR = 0.39, 95% CI: 0.19-0.78), independent of age and years lived with HIV.”
Humansindependent of age and years lived with HIVeach 5 years of ART usen = 223
HIV medicine
Antiretroviral therapy is associated with frailty in humans (third-line regimen).
“A CD4 count <200 cells/mm3, depression, low income, and use of third-line ART were variables significantly associated with a greater risk to present frail or prefrail status.”
Humansthird-line regimenthird-linen = 231
High Prevalence of Frailty and Prefrailty Status in Brazilian Patients Living with HIV
AIDS research and human retroviruses
Antiretroviral therapy raises the risk of frailty in humans (HIV).
“driven by factors, like chronic inflammation, antiretroviral therapy toxicity, and traditional risk factors.”
ReviewHIV
A Perspective on Frailty and its Predisposing Factors among People Living with HIV
Current HIV research
Metabolic syndrome
upin humans2OR 1.504
2 studies
Metabolic syndrome
upin humans2OR 1.504
Antiretroviral therapy is associated with metabolic syndrome in PLHIV in SSA.
“Longer ART duration, and in two Zambian studies, integrase inhibitor-based regimens (particularly dolutegravir) were associated with increased MetS risk”
Reviewin PLHIV in SSA
Research SquarePreprint
Antiretroviral therapy is associated with metabolic syndrome in humans (people living with HIV/AIDS; compared with no treatment) (pooled OR 1.504, 95% CI 1.217–1.859).
“ART exposure had 1.5 times greater odds of having MetS than nontreatment had”
Reviewpeople living with HIV/AIDS; compared with no treatment
BMC public health
Multimorbidity
downin humans1upin humans1
2 studies
Multimorbidity
downin humans1upin humans1
Antiretroviral therapy is associated with multimorbidity in people living with HIV.
“Initiating ART within 31-90 days after diagnosis was associated with reduced odds of multimorbidity”
Humansin people living with HIVwithin 31-90 days after diagnosis
Public health weekly report
Antiretroviral therapy is associated with multimorbidity in persons living with HIV (aRR 1.36, 95% CI 1.21-1.54).
“multimorbidity (aRR 1.36, 95% CI 1.21-1.54)”
Humansin persons living with HIV
BMC infectious diseases
Telomere length
upin humans1mixedin humans1
2 studies
Telomere length
upin humans1mixedin humans1
Antiretroviral therapy is associated with telomere length in PLWH.
“Initiation of antiretroviral therapy (ART) has been associated with partial recovery of TL”
Reviewin PLWH
Telomere length dynamics in adults living with HIV: A systematic review
BMC infectious diseases
Antiretroviral therapy is associated with telomere length in humans.
“Some studies found no association between antiretroviral therapy (ART) and telomere length shortening, while others found an association between ART and telomere length shortening.”
Review
Current issues in molecular biology
Atherosclerosis
downin humans1upin rhesus monkeys1
2 studies
Atherosclerosis
downin humans1upin rhesus monkeys1
Antiretroviral therapy is associated with atherosclerosis in rhesus monkeys (chronic SIV infection).
“Pathologic evaluation of a carotid artery from an SIV-infected, long-term ART-treated macaque revealed macrophage-rich plaques with p21+ senescent cells with intraluminal thrombus formation”
Animalschronic SIV infectioncarotid arterylong-term
Persistent activation of monocytes/macrophages and cell senescence in SIV-infected macaques on ART
Frontiers in immunology
Antiretroviral therapy lowers the risk of atherosclerosis in people living with HIV.
“Although contemporary ART decreases this enhanced risk, it inherently increases the risk for abnormal lipid profile, MetS, weight gain, and obesity.”
Reviewin people living with HIV
Cureus
Type 2 diabetes
upin humans2
2 studies
Type 2 diabetes
upin humans2
Antiretroviral therapy raises the risk of type 2 diabetes in humans (people living with HIV on antiretroviral therapy).
“Longer duration on ART, particularly > 5 or > 10 years, and specific ART regimens (e.g., those containing didanosine, stavudine, or PIs) were often associated with increased T2DM risk.”
Reviewpeople living with HIV on antiretroviral therapy> 5 or > 10 years
BMC infectious diseases
Antiretroviral therapy raises the risk of type 2 diabetes in older people living with HIV.
“the risks associated with Type 2 DM among older PLWH were long duration of HIV infection; the use of older-generation antiretroviral therapy; a high body mass index; the presence of hypertension”
Reviewin older people living with HIV
Risks of Type 2 diabetes among older people living with HIV: A scoping review
South African family practice : official journal of the South African Academy of Family Practice/Primary Care
Hypertension
upin humans2
2 studies
Hypertension
upin humans2
Antiretroviral therapy is associated with hypertension in persons living with HIV (aRR 1.52, 95% CI 1.22-1.89).
“hypertension (aRR 1.52, 95% CI 1.22-1.89)”
Humansin persons living with HIV
BMC infectious diseases
Antiretroviral therapy is associated with hypertension in people living with HIV in sub-Saharan Africa (1.23 times greater).
“1.23 times greater in individuals receiving antiretroviral therapy (ART)”
Reviewin people living with HIV in sub-Saharan African = 193,843
Scientific reports
Dyslipidemia
upin humans2+64% overall prevalence
2 studies
Dyslipidemia
upin humans2+64% overall prevalence
Antiretroviral therapy is associated with dyslipidemia in persons living with HIV (aRR 1.35, 95% CI 1.20-1.52).
“longer ART exposure was associated with dyslipidemia (aRR 1.35, 95% CI 1.20-1.52)”
Humansin persons living with HIV
BMC infectious diseases
Antiretroviral therapy is associated with dyslipidemia in humans (asymptomatic people living with HIV/AIDS) (64% overall prevalence).
“Our results showed a high prevalence of dyslipidemic individuals (64%), especially in those under ART.”
Humansasymptomatic people living with HIV/AIDSn = 94
Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA
Journal of applied biomedicine
Erectile dysfunction
upin humans1OR 1.62
1 study
Erectile dysfunction
upin humans1OR 1.62
Antiretroviral therapy is associated with erectile dysfunction in humans (men living with HIV) (OR 1.62, 95% CI 1.27–2.08).
“Erectile dysfunction is associated with age and with cardiometabolic, psychological, endocrine, and treatment-related factors.”
Reviewmen living with HIVmales
International journal of sexual health : official journal of the World Association for Sexual Health
Body weight
upin humans1
1 study
Body weight
upin humans1
Antiretroviral therapy is associated with body weight in humans (people with HIV).
“ART-associated weight gain is heterogeneous rather than a uniform restorative process.”
Reviewpeople with HIV
Antiretroviral therapy, adiposity, and cardiometabolic risk in people with HIV
The lancet. HIV
All 46Fewer
Funding
8 grants since 2018National Institute of Arthritis and Musculoskeletal and Skin Diseases$4.4MNational Institute on Drug Abuse$2.4MNational Institute of Dental and Craniofacial Research$1.9M
National Heart, Lung, and Blood InstituteJohns Hopkins University$199K2026–2030
Bone and fat cross-talk in antiretroviral therapy (ART) treated HIV patients
National Institute of Arthritis and Musculoskeletal and Skin DiseasesRush University Medical Center$143K2022–2027
National Institute of Allergy and Infectious DiseasesUniversity of Bristol$471K2024–2029
Novel mechanisms of muscle and bone loss with HIV infection, antiretroviral therapy, and aging.
National Institute of Arthritis and Musculoskeletal and Skin DiseasesAugusta University$608K2023–2028
Periodontitis as a comorbidity in SIV infection and Antiretroviral Therapy
National Institute of Dental and Craniofacial ResearchTulane University of Louisiana$611K2022–2027
Fogarty International CenterStellenbosch University$138K2023–2026
National Institute on Drug AbuseYale University$379K2018–2025
VetenskapsrådetKarolinska InstitutetSEK 24.9M2018–2023